Epratuzumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEpratuzumab
Drug Alias NameHumanized anti-CD22 monoclonal antibody IgG1依帕珠单抗Humanised monoclonal antibody LL2依普妥珠单抗epratuzumab +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD22 modulators
TargetsCD22
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[30] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUcb Biopharma SprlUcb PharmaGilead Sciences Inc +[5] 
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG